KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 4707 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Phase 3 randomized trial of postirradiation chemotherapy in patients with newly diagnosed ependymoma: A report from the Children's Oncology Group. PMID 41423745 · Neuro Oncol · 2026-May-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Marked survival gains in patients ≤ 65 years with advanced-stage mantle cell lymphoma: a pooled analysis of six randomized phase III trials, 1996-2020. PMID 41163573 · Haematologica · 2026-May-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 2 Figure · 8 Panel · risk visible
Segment 4b/5 Versus Wedge Resection for Gallbladder Adenocarcinoma: A Randomized Controlled Trial. PMID 40996213 · Ann Surg · 2026-May-01 The report is an eligible Phase III randomized trial with primary time-to-event efficacy endpoints (DFS and OS) in human oncology, but the intervention is purely surgical (liver resection techniques) and does not involve a drug-containing treatment arm, which is a mandatory criterion for inclusion.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Anti-PD-(L)1 plus chemotherapy in advanced PD-L1-negative nonsquamous non-small cell lung cancer: a systematic review and meta-analysis. PMID 42394449 · Immunotherapy · 2026-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Concordance between clinician-reported toxicities and patient-reported symptom severity in early-stage breast cancer: an analysis of the randomized phase III PANTHER trial. PMID 42215159 · ESMO Open · 2026-May The report is an original, randomized Phase III trial in oncology, but its primary endpoint is the concordance between clinician-reported toxicities and patient-reported symptom severity, not a time-to-event efficacy endpoint like OS, PFS, or DFS. It is therefore excluded as a secondary/safety analysis.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma, with or without peritoneal metastases: a post-hoc analysis on RATIONALE-305 study. PMID 42205142 · EClinicalMedicine · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
ARIAN protocol: a phase III study of sacituzumab and zimberelimab for the treatment of patients with non-small cell lung cancer. PMID 42159280 · Expert Opin Biol Ther · 2026-May 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma. PMID 42142358 · Future Oncol · 2026-May 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H S B
严格 v3 独有 eligiblephase3_publication_type no_km 0 Figure · 0 Panel · risk not_applicable
Mammographic surveillance in breast cancer patients aged 50 years or older: a synopsis of the Mammo-50 RCT. PMID 42116552 · Health Technol Assess · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Detection of Homologous Recombination Repair Gene Mutations by Tumor Tissue and Circulating Tumor DNA Testing in Prostate Cancer in the Phase III PROpel Trial. PMID 42114035 · JCO Precis Oncol · 2026-May The report is a subgroup/biomarker analysis of a Phase III trial, not a primary, interim, final, or updated efficacy result report. The required primary or key secondary time-to-event efficacy data are not presented in this abstract.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocols. PMID 42108644 · Future Oncol · 2026-May 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial. PMID 42069411 · Lancet Haematol · 2026-May The study is an oncology, human, randomized, phase 3, drug-intervention trial with original results. However, it fails the explicit time-to-event criterion. The primary endpoint is MR4.5, a molecular response rate (not time-to-event). No OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR is mentioned in the abstract. Therefore, is_eligible is null as metadata cannot establish the time_to_event criterion.
H L S B
旧组与严格 v3 交集 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B-Cell Lymphoma (CLSG-CNS-01): A Randomized, Multicenter, Prospective Phase 3 Trial. PMID 42062177 · Hematol Oncol · 2026-May 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 1 Figure · 2 Panel · risk unclear
On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials. PMID 42061373 · Lancet Oncol · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials. PMID 42061371 · Lancet Oncol · 2026-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Clonal Dynamics of Hematopoiesis in Aplastic Anemia after Immunosuppression and Eltrombopag. PMID 42047558 · NEJM Evid · 2026-May The study is a Phase 3 randomized trial with a drug intervention, but it does not report on a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) or include Kaplan-Meier or HR analyses. The endpoint is a biomarker analysis (clonal hematopoiesis dynamics).
H L S B
旧组与严格 v3 交集 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
The Association of p27 With Prostate Cancer Outcomes: A Secondary Analysis of NRG/RTOG 8610 and 9202. PMID 42006401 · Adv Radiat Oncol · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Mutation-Specific Response to Ramucirumab in EGFR-Mutated Metastatic NSCLC: Insights From Circulating Cell-Free DNA Profiling (Liquid Biopsy Japan Addendum of RELAY Phase 3 Randomized Study). PMID 42006277 · JTO Clin Res Rep · 2026-May The record is an updated biomarker analysis from a phase 3 trial, but it does not report a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier estimates or hazard ratios. The analysis focuses on circulating tumor DNA metrics and mutation rates.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial. PMID 41981308 · Nat Med · 2026-May 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 3 Figure · 8 Panel · risk visible
Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial. PMID 41969015 · Lancet Oncol · 2026-May The report is a secondary analysis from a Phase III RCT focusing on pain and quality-of-life endpoints, not the primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) required for inclusion.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial. PMID 41942646 · Nat Med · 2026-May 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type no_km 0 Figure · 0 Panel · risk not_applicable
Association Between Survival Benefits of Anticancer Drugs and Probability of US Food and Drug Administration Approval: A Systematic Review. PMID 41915314 · Pharmaceut Med · 2026-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib-rituximab versus fludarabine-cyclophosphamide-rituximab. PMID 41912408 · Br J Haematol · 2026-May 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type no_km 0 Figure · 0 Panel · risk not_applicable
Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial. PMID 41890705 · Blood Neoplasia · 2026-May 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 5 Figure · 11 Panel · risk unclear
Transanal total mesorectal excision versus laparoscopic total mesorectal excision for mid and low rectal cancer (COLOR III): short-term outcomes of an international, multicentre, phase 3, randomised, controlled, non-inferiority trial. PMID 41887239 · Lancet Gastroenterol Hepatol · 2026-May 干预为非药物单独策略,未满足药物干预要求。
H L S B
旧组与严格 v3 交集 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Systemic Therapy for Advanced Hepatocellular Carcinoma in 2026: Current Standard-of-Care and Emerging Therapeutic Strategies. PMID 41883115 · J Gastroenterol Hepatol · 2026-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial. PMID 41861615 · Int J Gynecol Cancer · 2026-May 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Phase III meta-analysis of first-line chemo-immunotherapy in ES-SCLC: Survival benefit without detectable class-level differences. PMID 41855713 · Lung Cancer · 2026-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Addition of zoledronic acid to consolidation chemotherapy in Ewing sarcoma-EURO EWING 2012 (EE2012): an international, open-label, randomised controlled phase III trial. PMID 41832299 · Br J Cancer · 2026-May 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III EGFR-mutated NSCLC: LAURA China cohort. PMID 41785639 · Lung Cancer · 2026-May 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer. PMID 41763609 · Ann Oncol · 2026-May 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Learning from late-stage trial failures in higher-risk myelodysplastic syndromes: towards adaptive and biomarker-enriched designs. PMID 41762737 · Expert Rev Anticancer Ther · 2026-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy of immune checkpoint inhibitors in the first line therapy of non-squamous non-small cell lung cancer: A systematic review and network meta-analysis. PMID 41720325 · Crit Rev Oncol Hematol · 2026-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Cytoreductive nephrectomy in the era of immune-checkpoint inhibitors: back to the future? PMID 41673778 · BJU Int · 2026-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Evaluating Post-Progression Survival in the Context of Progression-Free Survival Benefits: A Revisit of the CodeBreaK200 Design. PMID 41665865 · Ther Innov Regul Sci · 2026-May 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Statin use and outcomes in advanced prostate cancer:Secondary analysis of the SPARTAN trial. PMID 41654482 · Urol Oncol · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin-naïve Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). PMID 41633899 · Eur Urol · 2026-May 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Phase II Randomized Study of MK-2206 and Bicalutamide in Prostate Cancer Patients With Rising PSA After Primary Therapy (ECOG-ACRIN E2809). PMID 41609418 · Prostate · 2026-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。
H S B
严格 v3 独有 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. PMID 41571573 · Eur Urol · 2026-May 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Quality-adjusted progression-free survival analysis of veliparib and carboplatin/paclitaxel compared with chemotherapy alone in patients with newly diagnosed ovarian cancer (VELIA/GOG3005): ancillary analysis of a placebo-controlled, phase 3 randomized trial. PMID 41565553 · Int J Gynecol Cancer · 2026-May 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Nimotuzumab plus concurrent chemoradiotherapy sequential maintenance treatment for locally advanced cervical squamous cell carcinoma (NOTABLE-306): a multicenter, prospective, randomized, double-blind, placebo-controlled trial. PMID 41514314 · J Gynecol Oncol · 2026-May 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
Belantamab mafodotin, pomalidomide, and dexamethasone in Japanese patients with RRMM in the phase 3 DREAMM-8 trial. PMID 41493718 · Int J Hematol · 2026-May 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 1 Figure · 1 Panel · risk unclear
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study. PMID 41448362 · Ann Oncol · 2026-May 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
First-Line Anti-PD-1 Immunotherapy With Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma: A Meta-Analysis by PD-1 Subtype. PMID 41439745 · Urol Pract · 2026-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 trial. PMID 41422862 · Ann Oncol · 2026-May 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Long-term outcomes of S-1-based chemoradiotherapy in inoperable elderly patients with esophageal carcinoma: A multicenter, randomized, phase III clinical trial. PMID 41412437 · Radiother Oncol · 2026-May 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary End Points From the EMBARK Trial. PMID 41364813 · J Urol · 2026-May 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years. PMID 41239921 · J Eur Acad Dermatol Venereol · 2026-May The study is a randomized, Phase 3 trial of upadacitinib, but it is for atopic dermatitis (non-oncology) and is a safety analysis, not an efficacy analysis with a primary time-to-event endpoint.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-Term Performance of Prognostic Models for Advanced Renal Cell Carcinoma in the Era of Improved Survival With Immune Checkpoint Inhibitors. PMID 40658913 · JCO Oncol Pract · 2026-May 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H L S B
旧组与严格 v3 交集 eligibleexplicit_phase3_randomized needs_review 1 Figure · 1 Panel · risk unclear
Medial retropharyngeal nodal region sparing radiotherapy in nasopharyngeal carcinoma: five year analysis of open label, non-inferiority, multicentre, randomised phase 3 trial. PMID 41916649 · BMJ · 2026-Mar-31 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 1 Figure · 4 Panel · risk unclear